1. Scrip
  2. >>R&D

Madrigal May Shake Up NASH Race With Phase II Resolution Data

 
• By Joseph Haas

Madrigal reports data showing that MGL-3196 resolved non-alcoholic steatohepatitis and improved key secondary measures, data that suggest a better effect than other NASH candidates.

scientists doing lab research on digital screen

Throwing a potential upset in the emerging non-alcoholic steatohepatitis (NASH) market, Madrigal Pharmaceuticals Inc.’s selective thyroid hormone receptor beta agonist reported Phase II data May 31 that surpass trial results for other NASH candidates, showing that MGL-3196 can resolve NASH and that 12-week liver fat-reduction data correlate to 36-week histologic improvements in NASH patients.

Although four other companies already have begun Phase III work in NASH and nothing Madrigal can do will position MGL-3196...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

More from Scrip

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By Mandy Jackson

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.